Article

Predicting Cost-Effectiveness of Generic Versus Brand Dabigatran Using Pharmacometric Estimates among Patients with Atrial Fibrillation in the United States

2019-09-20

Abstract excerpt

<h4>ABSTRACT</h4> Generic entry of newer anticoagulants is expected to decrease the costs of atrial fibrillation management. However, when making switches between brand and generic medications, bioequivalence failures are possible. The objectives of this study were to predict and compare the lifetime cost-effectiveness of brand dabigatran with hypothetical future generics. Markov micro-simulations were modified to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dac3c912-629d-5530-901e-c535bc04b930
DOI: 10.1101/19006346

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 10 closest

Predicting Cost-Effectiveness of Generic Versus Brand Dabigatran Using Pharmacometric Estimates among Patients with Atrial Fibrillation in the United StatesDOI 10.1101/19006346Read

Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.Semantic proximity Read

Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.Semantic proximity Read

Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis.Semantic proximity Read

Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the USSemantic proximity Read

Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System.Semantic proximity Read

Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation.Semantic proximity Read

Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis.Semantic proximity Read

Testing antiplatelets generics beyond bioequivalence: A parallel single-blinded randomized trialSemantic proximity Read

Availability of Different Branded Generic Vildagliptin after Off-patenting: An Observation from Eastern IndiaSemantic proximity Read

Cost-Utility Analysis of Cryoballoon Ablation versus Radiofrequency Ablation in the Treatment of Paroxysmal Atrial Fibrillation; Case Study: IranSemantic proximity Read